Log in to save to my catalogue

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivota...

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivota...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_26e8df351a78481d84b79ca3e21d57c8

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL)....

Alternative Titles

Full title

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_26e8df351a78481d84b79ca3e21d57c8

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_26e8df351a78481d84b79ca3e21d57c8

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-023-01470-0

How to access this item